Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Neurofibromatosis Type 1 (NF-1)
100%
Neurofibromatosis Type I
71%
Neurofibromatosis Type 2
31%
Schwannomatosis
30%
Tumor
30%
Cutaneous Neurofibroma
27%
Clinical Trials
22%
Plexiform Neurofibroma
20%
Neurofibromatosis
20%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
20%
Glioma
13%
Vestibular Schwannoma
13%
Bevacizumab
11%
Peripheral Nerve Sheath Tumor
10%
Amide Proton Transfer-weighted Imaging
10%
Temozolomide
9%
High-grade Glioma
9%
Brain Tumor
7%
Schwann Cells
7%
NF-2
7%
Consensus Recommendations
7%
Neuro-oncology
7%
Type I Neurofibromatosis
7%
Type 1 Neurofibromatosis
7%
Schwannoma
7%
Cardiac Magnetic Resonance Imaging (cMRI)
6%
Newly Diagnosed
6%
Malignant Glioma
6%
Neurofibromatosis Type
6%
Meningioma
6%
Glioblastoma
5%
Patient-reported Outcomes
5%
Neoplasms
5%
Patient-Reported Outcomes Measurement Information System (PROMIS)
5%
NF2-related Schwannomatosis
5%
Neurofibroma
5%
Radiation Therapy
5%
Medicine and Dentistry
Neurofibromatosis Type I
75%
Plexiform Neurofibroma
47%
Tumor
33%
Neoplasm
31%
Schwannomatosis
31%
Neurofibromatosis Type II
27%
Clinical Trial
26%
Neurofibromatosis
25%
Ganglioglioma
20%
Malignant Peripheral Nerve Sheath Tumor
16%
Magnetic Resonance Imaging
16%
Peripheral Nerve
15%
Nerve Sheath Tumor
14%
Vestibular Schwannoma
12%
Genetics
11%
Glioblastoma
10%
Neuro-Oncology
9%
Intracranial Tumor
9%
Neurinoma
8%
Carboxamide
8%
Proton Transport
7%
Temozolomide
7%
Quality of Life
7%
Meningioma
6%
Diseases
6%
Bevacizumab
6%
Biological Marker
6%
Patient-Reported Outcome
6%
Radiation Therapy
6%
Clinician
5%
Schwann Cell
5%
Cancer
5%
Malignant Neoplasm
5%
